The growing range of biologic disease-modifying antirheumatic drugs (DMARDs) has greatly improved the treatment landscape for juvenile idiopathic arthritis (JIA). However, certain subsets of patients with JIA remain unresponsive to these therapies and require alternate treatment strategies.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045